Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.55 |
| ▸ | F12 | P00748 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 7/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | DDO | Q99489 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30395353 | 1.00 | NPC1 (0.66) | NPC1RAB9ALMNASMN1; SMN2SMYD3 | |
| SCHEMBL21639712 | 0.90 | MAOA (0.58) | NPC1RAB9ALMNASMN1; SMN2SMYD3 | |
| SCHEMBL486475 | 0.90 | MAOB (0.56) | NPC1RAB9ALMNASMN1; SMN2SMYD3 | |
| SCHEMBL16627755 | 0.89 | MAOA (0.57) | NPC1RAB9ALMNASMN1; SMN2SMYD3 | |
| SCHEMBL16627875 | 0.89 | ADORA3 (0.53) | NPC1RAB9ALMNASMN1; SMN2SMYD3 | |
| SCHEMBL34468802 | 0.89 | MEN1 (0.54) | NPC1RAB9ALMNASMN1; SMN2SMYD3 | |
| SCHEMBL34468752 | 0.85 | MAOB (0.60) | NPC1RAB9ALMNASMN1; SMN2SMYD3 | |
| SCHEMBL16627766 | 0.85 | NPC1 (0.49) | NPC1RAB9ALMNASMN1; SMN2SMYD3 | |
| SCHEMBL16627822 | 0.84 | MAPT (0.58) | NPC1RAB9ALMNASMN1; SMN2SMYD3 | |
| SCHEMBL21639567 | 0.84 | EGFR (0.54) | NPC1RAB9ALMNASMN1; SMN2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159493-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-05-25 | — | — | US | disclosed |
| US-20230159493-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-05-25 | — | — | US | disclosed |
| US-20230159493-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-05-25 | — | — | US | disclosed |
| EP-3143399-A1 | BIOMARKERS PREDICTIVE OF LUPUS PROGRESSION AND USES THEREOF | Biogen MA Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015175424-A1 | BIOMARKERS PREDICTIVE OF LUPUS PROGRESSION AND USES THEREOF | BIOGEN MA INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015050379-A1 | NOVEL QUINOLINONE DERIVATIVE AND USE THEREOF | 광주과학기술원 | 2015-04-09 | — | — | WO | disclosed |
| EP-1517896-A2 | PHENYL- AND PYRIDYL-DIAZAHETEROCYCLES HAVING A TNF-MODULATING ACTIVITY | Sanofi-Aventis (FR) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003106425-A2 | PHENYL- AND PYRIDYL-DIAZAHETEROCYCLES HAVING A TNF-MODULATING ACTIVITY | SANOFI-SYNTHELABO (FR) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159493-A1 | AHR AGONISTS | AHR, ARNT, RORC | NPC1 1273/4885RAB9A 3565/4885LMNA 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.